Library

Place of publication:
Effective pharmacotherapy, 2022

Summary:
the article is devoted to the complex therapy of primary open -angle glaucoma, namely, the understanding of the principles of neuroprotection in the pathogenesis of the development of the glaucoma of optical neuropathy. Various biochemical reactions are described that are involved in the apoptosis of the layer of nerve fibers of the retina and the processes of neurodegeneration. In the Russian Federation, a reference (original) antioxidant with a multimodal mechanism of action of Mexidol (ethylmethylhydroxypyridine is actively used in the Russian Federation. Due to its unique complex molecule - the pyridine base and derivative of amber acid, Mexidol is characterized by high bioavailability and the ability to penetrate through the hematoencephalic barrier. The presence of succinate in the molecule also enhances the antioxidant effect, which fundamentally distinguishes the drug from other antioxidant analogues presented in the domestic pharmaceutical market. The mechanism of action of Mexidol is based on antioxidant, antihyplance and membrane effects. The use of Mexidol, which affects different links of oxidative stress, is justified in the complex treatment of primary open -angle glaucoma. It is no coincidence that the drug is included in the standards of medical care in patients with glaucoma. An analysis of a number of publications containing the results of studies of ethylmethylhydroxypyridine of succinate in the primary open-angle glaucoma of the I-III stages. A consistent scheme of therapy with Mexidol with proven effectiveness, slowing down the processes of neurodegeneration and stabilizing visual functions in patients with primary open -angle glaucoma, has been developed. Keywords: glaucoma, Mexidol, antioxidant, neuroprotection, oxidative stress.

Place of publication:
Bulletin of ophthalmology, 6, 2015

Summary:
the goal is to develop an algorithm for neuroprotective treatment during the dispensary observation of railway workers with primary open -angle glaucoma (s) based on an assessment of the effectiveness of the phased use of intravenous and tablet forms of the drug Mexidol. Material and methods. The study included patients - workers of various professions of the Russian Railways company with stages I - III with a compensated level of intraocular pressure (IOD). Mexidol was prescribed 250 mg intravenously drip for 5 days in a daily hospital mode, then an outpatient basis 125 mg 3 times a day for 3 months. In the first, second and third visits, patients conducted a comprehensive ophthalmological examination using high -tech control methods. Results. Analyzed data from 58 patients (96 eyes). A reliable improvement of perimetry indicators, optical coherent tomography was received only to the third visit, at the end of the course of treatment with a tablet form of Mexidol. In patients with the I - II stage of the disease, the greatest effect of neuroprotective therapy was noted. Conclusion. The results obtained during the study allow us to recommend the appointment of patients with soup both combined therapy with Mexidol - injection and tablet forms, and long (3 months) isolated use of the tablet form of the drug. Neuroprotective therapy with Mexidol is most effective in the early stages of the disease.

Place of publication:
Labor hygiene and medical ecology. No. 2 (47), 2015

Summary:
the article analyzes the results of an open comparative study of the effectiveness and safety of the drug Mexidol in a dosage form for injection as part of therapy in patients with open -angle glaucoma of various stages. During the clinical study, the good tolerance of the drug Mexidol in the dosage form is confirmed by the injection solution when prescribing it to patients with various stages of open -angle glaucoma in doses of 100-300 mg/day. intramuscularly within 14–21 days. It was proposed to include Mexidol, a multifaceted effect, in the composition of the complex therapy of patients of various stages, which has a multifaceted effect. The identified unwanted phenomena related to the prescription of this therapy are not serious, and the probability of their appearance is taken into account in the instructions for the medical use of the studied drugs. Thanks to membrane, nootropic, anti -hypoxic and antioxidant effects, Mexidol is recommended to be used in the complex therapy of optical neuropathy in the early and later stages of the disease.

Place of publication:
Russian Glack School, Glaucoma Conference Theory and Practice. No. 8, 2013, p. 33-37.

Summary:
Purpose of the study. To study the effectiveness of the drug Mexidol in the complex treatment of primary open -angle glaucoma. Materials and methods. The study included patients from 55 to 75 years with a diagnosis of signs I-III Art. on both eyes, with a normalized level of IOA (not more than 21 mm Hg according to Goldman); not having a serious ophthalmic and general somatic pathology that affects the course and results of the study; Benzodiazepine anxiolytics, anticonvulsant and anti -parquinsole drugs that do not use as concomitant therapy, as well as the last 3 months that do not participate in another clinical study.

Place of publication:
Bulletin of ophthalmology, No. 2, 2013

Summary:
The purpose of this study is to study the effectiveness and safety of the use of Mexidol as part of combined treatment of primary open -angle glaucoma (s). The study was involved in 94 patients (185) aged 18 to 75 years with the I -III staging, which were divided into 3 groups: 50 patients were prescribed combined treatment of 100 mg of Mexidol and 150 mg of picmilon, 22 patients took 300 mg of Mexidol and 150 MG picmilon, 22 patients received only 150 mg of picclon. Patients took drugs once a day for 14 or 21 days. The examination included standard ophthalmological, as well as perimetry, electroretinography, the study of the arterial blood flow of the retina and the optic disk. After taking combination therapy, an improvement in visual acuity, perimetry, electrophysiological parameters and increasing the velocity of arterial blood flow in the retina were recorded. Thus, combined therapy allows you to improve the treatment of patients with soup.

Place of publication:
experimental and clinical pharmacology, volume 75, No. 7, 2012, p. 20-26

Summary:
a prospective randomized simple “blind” controlled study of the influence of domestic derivatives of 3-oxypyrididine and ambercal acid (Emoxypin, Reimberin, Mexidol) on the effectiveness of the complex treatment of patients with primary open-angle glaucoma (Lugus) was carried out. It was established that the two-week intravenous administration of 3-oxypyridine derivatives (Emoxypin and Mexidol) has a retinoprotective effect after 14 days from the beginning of treatment with 3 months delayed by 3 months changes in blood flow velocity in the central artery of the retina (CAS). The rectinoprotective effect of Emoxypin (a single dose of 150 mg) was manifested by a decrease in the horizontal dimensions of a blind spot after 2 weeks, followed by a decrease in the ultimate diastolic velocity of the blood flow in the CAS, 3 months after the end of infusion therapy. The use of Mexidol (a single dose of 300 mg) after 14 days from the start of treatment caused an expansion of the total field of view when using a test object with an area of ​​16 mm2 with a concomitant decrease in the threshold of the optic sensitivity of the optic nerve and a decrease in the severity of the Lugus-Associated hypotimia. 3 months after the end of the introduction of Mexidol, all speed indicators of blood flow to the CAS increased. Reimberin (a single dose of a 400 ml of a 1.5% solution of reamberin, representing a combination of polyelectric mixture of sodium meglumin of succinate) did not have a retinoprotective effect, but caused prospective changes in the lipid spectrum of blood and an increase in the ultimate diastolic velocity of blood flow to the CAS. Mexidol, at the same time, which is a derivative of 3-oxypyridine and amber acid, exceeds the isolated derivatives of 3-oxypyrididine (emoxypin) and amber acid (reamberin) in terms of the severity of the retinoprotective effect, a positive effect on the condition of the optic nerve and the mood of patients of the soup.

Place of publication:
Bulletin of ophthalmology, No. 4, 2012

Summary:
a prospective placebo-controlled simple blind randomized study of the influence of Mexidol (2-ETIL-6-methyl-3-hydroxypyrididine of the succinate) on the dynamics of the optic nerve and high-speed blood flow and orbit arteries in comparison with changes in indicators of the networks of luminosity of the networks of luminosity of the networks of luminous sensitivity , visual acuity and size of the visual fields with a course intravenous introduction of Mexidol against the background of standard therapy of primary open -angle glaucoma. It was established that the intravenous administration of Mexidol in a single dose of 300 mg after 14 days from the onset of treatment causes a decrease in the threshold of electrical sensitivity of the optic nerve and the concomitant expansion of the total field of view when using a test object with an area of ​​16 mm ² . These effects of Mexidol were not accompanied by changes in blood flow in the arteries of the eyeball and orbit, were transient and leveled 3 months after the end of therapy. The delayed vasotropic effect of Mexidol was manifested by an increase in blood flow velocity in the central artery of the retina 90 days after the completion of infusion therapy.

Place of publication:
Clinical ophthalmology volume 12, No. 3, 2011

Summary:
the incidence of primary open-angle glaucoma (s) to this day is one of the most important medical and social problems. Glaucoma is one of the leading causes of blindness in developed countries, therefore, issues of improving the diagnosis and treatment of this disease are extremely relevant. The etiopathogenesis of glaucomas is complicated and, despite numerous studies, has not been fully studied. There is every reason to believe that it has a multifactor character. Glacker optical neuropathy (Gon) is due to the action of various factors leading to the apoptosis of the ganglion cells of the retina: with pressure of the optic nerve axons in the openings of the ethmoid plate due to increased intraocular pressure (IPD), impaired blood supply to the optic head, the formation of an excess of free radicals, in the way of ischemia and increased peroxidation of lipids (floor). With ischemia in the nervous tissue, protein synthesis is inhibition and the activation of anaerobic glycolysis, then the work of K-NA pumps and depolarization of cell membranes occurs. In response to this, a glutamate is released, which activates neurons through NMDA receptors, leading to an excessive amount of calcium ions into the cage. Excessively high concentration CA2+ in cells triggers the activation of complex nuclease cascades, protease and lipase. They directly affect intracellular proteins and lipids, as a result of which active free radicals are formed, as well as an excessive amount of nitrogen oxide (No), which can contribute to the development of the race. Various active forms of oxygen are formed, which have a cytotoxic effect on the retina, visual nerve, lead to destructive changes in the drainage system. In fact, mechanical and vascular factors realize their effects through metabolic processes.

Place of publication:
therapy No. 8 (70) 2023

Summary:
Annotation. Chronic brain ischemia (Khim) is one of the most common neurological pathologies. Its development is affected by many factors, among which arterial hypertension (AH) occupies a special place. Him contributes to cognitive impairment, negatively affects the quality of life and leads to motor and psycho -emotional disorders. In the aspect of the therapy of this condition, an important role belongs to neuroprotectors and, in particular, the use of ethylmethylhydroxypyridine of succinate (Mexol ^® , NPK Pharmasoft LLC, Russia), which has a multimodal effect and confirms its high efficiency in a large number of clinical studies. The evidence base of ethylmethylhydroxypyridine of the succinate, including in the study of Memo, indicates the particularly high effectiveness of the drug among patients with Khim and AG: they have Mexol ^® significantly improves cognitive functions, reduces the level of anxiety and asthenia and improves the quality of life. With this in mind, the drug can be recommended for use in complex therapy of chemicals, especially in patients with AG. Keywords: chronic brain ischemia, ethylmethylhydroxypyridine succinate, Mexidol ^® , arterial hypertension, cognitive functions.

Authors:
V.V. Zakharov ¹ , O.D. Ostroumova ^1.2 , A.I. Kochetkov ² , M.V. Klepikov ² , A.I. Fedin ³

¹ FGAOU VO "First Moscow State Medical University named after THEM. Sechenov »Ministry of Health of Russia (Sechenov University);
² FSBEI of DPO “Russian Medical Academy of Continuing Professional Education” of the Ministry of Health of Russia, Moscow;
³ FGAOU in Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow

Place of publication:
therapy No. 1 (63) 2023

Summary:
Annotation. Chronic brain ischemia (Khim) is one of the most common in the clinical practice of neurological pathological conditions. The goal is to evaluate the effectiveness and safety of sequential therapy with Mexidol ^® intravenously and Mexidol ^® Fort 250 oral in groups of patients with arterial hypertension (AH) and without the aspect of the drug on cognitive functioning, as well as the severity of asthenic, anxiety, autonomic and motor disorders, and Quality of life in a chemical conditions. Material and methods. Within the framework of subanalysis, patients with chemicals were divided into 4 subgroups: 1st-patients with AH who received drugs Mexidol ^® and Mexidol ^® Forter 250 (n = 144); 2nd-patients with AG who received placebo (n = 146); 3rd-patients without hypertension receiving Mexidol ^® and Mexol ^® Fort 250 (n = 15); 4th-patients without hypertension receiving placebo (n = 12). Results. At the end of the observation period, statistically significant differences in the dynamics of the Mosa scale between groups of patients receiving Mexidol ^® and placebo (p = 0,000), indicating the superior effectiveness of the use of Mexidol in the subgroup of patients with AH, were identified. Against the background of therapy with Mexidol ^® , unlike placebo, the median value of the point on the Mosa scale at the end of the observation period reached the level of norm in all patients. When assessing the secondary endpoints of effectiveness, the statistically significant advantage of Mexidol over the placebo in the population of patients with AH at the final visit was achieved by the following parameters: a test of digital characters, an asthenication scale MFI-20, a Bek anxiety scale, a tinetti scale, and a psychological component of health according to the questionnaire according to the questionnaire SF-36. The comparable nature of the safety profile of Mexidol and placebo is established. Conclusion. The results give reason to recommend the long-term consistent use of the drug Mexidol ^® in the complex treatment of patients with hypertension as an instrument for protecting the brain as an organ-canal and means of pathogenetically substantiated therapy of cognitive, emotional, asthenic, vegetative and motor disorders. Keywords: chronic brain ischemia, arterial hypertension, cognitive disorders, ethylmethydroxypirinate, Mexidol ^® , Mexidol ^® Fort 250.

Authors:
N.N. Zavadenko ¹ , N.Yu. Suvorinova ¹ , T.T. Batysheva ² , O.V. Bykova ² , A.N. Platonova ² , D.D. Gainetdinova ³ , E.V. Levitina ⁴ , V.V. Machines ⁵ , I.N. Vakula ⁶ , N.E. Maksimova ⁷

¹ FGAOU in Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia;
² GBUZ "Scientific and practical center of children's psychoneurology of the Department of Health of Moscow", Moscow, Russia;
³ FSBEI in Kazan State Medical University of the Ministry of Health of Russia, Kazan, Russia;
⁴ FSBEI in Tyumen State Medical University of the Ministry of Health of Russia, Tyumen, Russia;
⁵ FSBEI in Ulyanovsk State University, Ulyanovsk, Russia;
⁶ LLC "Center for Professional Therapy", Krasnodar, Russia;
⁷ FSBEI in the Tver State Medical University, Tver, Russia

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2022, T.122, No. 4

Summary:
Purpose of the study. Evaluate the effectiveness and safety of two dosing modes of the drug Mexidol tablets covered with a film shell, 125 mg (NPK Farmasoft LLC, Russia), compared with placebo, in children with attention deficit (ADHD) from 6 to 12 years. Material and methods. The study was carried out in 14 clinical centers of the Russian Federation as a multicenter randomized double-blind, placbo-controlled double-controlled in 3 parallel groups. The study was attended by 333 children aged 6 to 12 years with a confirmed diagnosis of ADHD, established in accordance with the criteria of the ICD-10 and DSM-5. After screening (up to 14 days), patients were randomized in 3 groups in a ratio of 1: 1: 1: Mexidol 125 mg 2 times a day, Mexidol 125 mg 1 time per day+placebo and placebo. The duration of treatment in all groups was 42 days. The study was completed by 332 children. The dynamics of the state was evaluated by the scales of the ADHD assessment and related disorders. Results. Statistically significant changes in the amount of the total score on the subx “Inattentiveness”, “Hyperactivity impulsivity” of the ADHG assessment scale through 6 weeks of therapy in all three groups of the study (P <0.05). At the same time, between the groups of Mexol 125 mg 1 time per day+placebo and placebo, as well as between Mexol groups 125 mg 2 times a day and placebo, expressed statistically significant differences were observed (for the PP: P = 0.000308 and P = 0.000024 Accordingly, for the population FAS: P = 0.000198 and P = 0.000024, respectively), which indicates the superiority of the therapy with Mexidol. According to most secondary criteria for effectiveness (average changes in points on the “Inattention” Snap-IV scale, the average change in scores “Hyperactivity impulsiveness” of the SNAP-IV scale, the average change in the cones index of the SNAP-IV scale, the average change in the value On the ADHD Rating Scale IV scale, assessments on the scale of the general clinical impression of the severity of ADHD, estimates on the general clinical impression scale - improvement) were also obtained statistically significant differences (p <0.05) when comparing the treatment of Mexido with placebo. The results of a statistical analysis of the frequency of the occurrence of undesirable phenomena, indicators of laboratory tests, and a physically examination demonstrate the absence of significant differences between compared groups in basic safety indicators. Conclusion. The treatment regimen with Mexol, tablets covered with a film shell, 125 mg 2 times a day, showed an advantage over Mexol's scheme tablets covered with a film shell, 125 mg once a day+placebo. A comparable nature of the security profiles of the studied dosing of the drug Mexidol and placebo was obtained. Keywords: attention deficit syndrome with hyperactivity, inattention, hyperactivity, impulsiveness, children, pharmacotherapy, ethylmethydlhydroxypyridine succinate, Mexidol.

Authors:

Dhruv Sanjay Gupta, Siddhi Bagwe Parab, Ginpreet Kaur

Translated from Zhurnal Nevrologi I Psikhiatrii Imeni SS Korsakova, Vol. 121, no. 12, ISS. 2, pp. 69–76,
December 2021. Original Article Submitted December 20, 2021. Accepted December 22, 2021.

Place of publication:
Neuroscience and Behavioral Physiology, Vol. 52, no. 5, June, 2022

Summary: Emoxypine and Its Succinate Derivative Share a Common Hydroxypridine Structure, Which Is to Pyridoxine. Thus compounds have been Utilized therapeutically and industrially, Owing to the Wide Range of Properties Offorded. This Includes Antihypoxic, Neuroprotective and Cardioprotective Effects, Along with Pharmacokinetic Benefits Such as the Blood Brain Brain Brain, O Wing to Its Relatively Small Size and Low Molecular Weight. IT Was Observed that Emoxypine Exhibited Iron Chelating Property in Vitro, Indicating Its Usage as a Promising Therapeutic Strategy in the Management of Neurodegenerate ONS SUCH ALZheimer's Disease (Ad), As Well as Hematologic Disorders Like Thalassemia and Hemochromatosis. In Addition to this, it has been Observed to Exert Antioxidant Effect, TheFore, It May BE Considered for the Amelioration of Disoraders Resulting From Free Radical Injury. Studies on Its Mechanism of Action and Implications on Cellular and Molecular Levels Would Help To Further The Understanding of Its Benefits, AS Soles Proospects for For Novel Applications. The Primary Focus of this Review is to dress on the Broad SPACTRUMACOLOGICAL Properties Offered BY Emoxypine and Its Succinate Derivative, and To HIGHHLIGHT THE Cope for An Increased Number of Pre-Clinical and Clinical Trite Assess Its Safety and Efficacy. In Addition to this, The Highlights of this Article Include the Recent Patents Field and Scope for Novel Applications of these Agents.  Keywords: NeuroinflamMation, Mitochondrial Dysfunction, Iron Overload, Mexidol, Acute Kidney Injury, Cerebrooprotection

Authors:
A.I. Fedin ¹ , V.V. Zakharov ² , M.M. Tanashian ³ , E.I. Chukanova ¹ , E.N. Majidova ⁴ , L.A. Shchepankevich ^5.6 , O.D. Ostroumova ⁷

¹ FGAOU in Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia;
² FGAOU VO "First Moscow Medical University named after THEM. Sechenov »Ministry of Health of Russia (Sechenov University), Moscow, Russia;
³ FGBNU "Scientific Center for Neurology", Moscow, Russia;
⁴ Tashkent Pediatric Medical Institute of the Ministry of Health of the Republic of Uzbekistan, Tashkent, the Republic of Uzbekistan;
⁵ FSBEI in Novosibirsk State Medical University of the Ministry of Health of Russia, Novosibirsk, Russia;
⁶ FGBNU "Federal Research Center for Fundamental and Transalized Medicine", Novosibirsk, Russia;
⁷ FSBEA DPO “Russian Medical Academy of Continuing Professional Education” of the Ministry of Health of Russia, Moscow, Russia

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2021, T.121, No. 11

Summary:
Purpose of the study. To evaluate the effectiveness and safety of consistent therapy with the drug Mexidol intravenously and Mexidol Forte 250 orally in patients with chronic brain ischemia.

Material and methods. In the international multicenteric randomized double-blind-controlled study, 318 patients with a chemical place from 40 to 90 years are included in 15 clinical centers, located in the territory of the Russian Federation and the Republic of Uzbekistan. Patients were randomized in 2 groups, patients of the 1st group received Mexidol intravenously 500 mg once a day for 14 days, then Mexidol Forte 250 was prescribed orally 250 mg 3 times a day for the next 60 days; Patients of the 2nd group received placebo in a similar mode. As the primary criterion for effectiveness, the average value of the change in the point on the MOCA scale was chosen at the stage of completion of the study by the patient compared to the initial level.

Results. Upon completion of the study between the 1st and 2nd groups, reliable differences were identified by the result of the MOCA scale (p <0.000001). The lower boundary of 95% of the trust interval for the difference in the average indicators of the main criterion for the effectiveness between the 1st and 2nd groups was 1.51, which allows the higher efficiency of the use of Mexidol. According to the secondary endpoints, a statistically significant advantage over the placebo at the final visit was achieved by the following parameters: a test of digital symbol replacements, an asthenia assessment scale, a Bek anxiety scale, a tineta questionnaire, a Tinetti scale, a SF-36 questionnaire (psychological component of health), and a psychological component of health). CGI scale (a general clinical impression scale). The comparable nature of the safety profile of Mexidol and placebo is established.

Conclusion. The validity and expediency of the consistent use of Mexidol and Mexidol Forte 250 in the treatment of patients with chemicals are demonstrated.

Keywords: chronic brain ischemia, cognitive disorders, neuropsychological testing, ethylmethylhydroxypyrididine succinate, Mexidol, Mexidol Forte 250, treatment of chemicals, examination of memes.

Place of publication:
Infectious diseases, 2021, T. 19, No. 1, P. 159–164

Summary:
the new coronavirus infection Covid-19 is characterized by high mortality and the absence of effective etiotropic therapy. Activation of oxidative stress may be one of the links in the pathogenesis of organ damage against the background of this infection. Target. Assessment of the ability of the drug Mexidol ^® to influence the speed of clinical improvement in pneumonia in hospitalized patients with a new Covid-19 coronaviral infection. The study includes 62 patients over the age of 18 years with a confirmed new coronavirus infection COVID-19 according to computed tomography (CT) of the lungs (stages KT1, KT2, KT3) and studies by the polymerase chain reaction from the nasopharynx and oropharynx on the SARS virus RNA SARS COV-2. After randomization, patients of the 1st group received infusion of Mexidol at a dose of 1000 mg/day for 7 days, patients of the 2nd group-infusion of isotonic sodium chloride solution. Compared to the control group in patients who received therapy with Mexidol, a reliably more pronounced decrease in body temperature, and a tendency to reduce the severity of shortness of breath were noted. In the Mexidol group, the concentration of superoxidsmutase has not changed, while in the control group there was a tendency to reduce it, the C-reactive protein decreased 2.2 times more than in the control group (p = 0.09). The tendency to a more rapid decrease in ferritin in the active intervention group has been identified. Mexidol therapy can have a positive effect on the clinical manifestations and the severity of laboratory-inflammatory syndrome in patients with a new Covid-19 coronaviral infection. Key words: new coronavirus infection Covid-19, oxidative stress, Mexidol.

Place of publication:
Medical alphabet No. 19/2017, volume No. 3. Emergency medicine

Summary:
relevance. Neuroprotection is a mandatory component of intensive care of cerebral disasters in the prehospital and hospital stages of medical care. Target. Identification of the characteristics and adequacy of the ambulance personnel of the methods of neuroprotheres in various cerebral disasters. Materials and methods. To determine the level of knowledge and practical skills of neuroprotection of various cerebral disasters, anonymous voluntary questioning of 109 doctors of the SMP stations and 103 paramedics of the Voronezh city ambulance station was carried out. The effectiveness of the use of neuroprotectors for cerebral disasters was studied using a special protocol attached to the Chargage map of the Voronezh ambulance station. Results. Theoretical training in the neuroprotection section is considered sufficient 75 % of doctors and 57 % of paramedics. 25 % of doctors and 35 % of paramedics are considered insufficient theoretical training. The use of Mexidol intensive therapy in the intensive care of the prehospital stage has a pronounced positive clinical effect.

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2021, T. 121, No. 10, Issue. 2

Summary:
in a review article, modern approaches to testing and registration of reproduced (generic) drugs are considered. The history of the formation of a methodology for research of reproduced drugs and modern legislation of the Russian Federation is presented. The stages of confirmation of the equivalence of original and reproduced drugs are described: pharmaceutical equivalence, bioequivalence and therapeutic equivalence. Methods of evaluating bioequivalence as a basic study in the registration of reproduced drugs are analyzed in detail. On the example of the original domestic neuroprotector of the drug Mexidol (ethylmethylhydroxypyrididine of succinate) and its generiks described how legislative acts are implemented in practice. It is concluded that not all reproduced drugs can be interchangeable with the original drug.

Keywords: original and reproduced drugs, generics, ethylmethylhydroxypyridine succinate, Mexidol.